Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019045431) MACROLIDE ANTIBIOTIC REACTIVE MARKER OF HELICOBACTER PYLORI
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/045431 International Application No.: PCT/KR2018/009946
Publication Date: 07.03.2019 International Filing Date: 29.08.2018
IPC:
C12Q 1/689 (2018.01) ,C12Q 1/686 (2018.01)
[IPC code unknown for C12Q 1/689][IPC code unknown for C12Q 1/686]
Applicants:
주식회사 엠모니터 MMONITOR INC. [KR/KR]; 대구시 달서구 성서공단로11길 62, 633호 #633, 62, Seongseogongdan-ro 11-gil Dalseo-gu Daegu 42713, KR
Inventors:
전효성 JEON, Hyo Sung; KR
김서현 KIM, Seo Hyeon; KR
Agent:
박원미 PARK, Weonmee; KR
Priority Data:
10-2017-010986930.08.2017KR
10-2018-001502407.02.2018KR
Title (EN) MACROLIDE ANTIBIOTIC REACTIVE MARKER OF HELICOBACTER PYLORI
(FR) MARQUEUR RÉACTIF ANTIBIOTIQUE MACROLIDE D'HELICOBACTER PYLORI
(KO) 헬리코박터 파이로리의 마크롤라이드계 항생제 반응성 마커
Abstract:
(EN) Disclosed, in the present invention, are a composition for predicting clarithromycin susceptibility and resistance of Helicobacter pylori comprising a substance for detecting 23S rRNA gene haploid in which the bases at positions 2143 and 2182 of gene encoding bacterial 23S rRNA are A and T, or G and C, respectively; and a method for predicting clarithromycin reactivity using the composition. The composition and the method according to the present invention can predict the clarithromycin reactivity of Helicobacter pylori with high accuracy, and thus can improve the success rate of first-line eradication treatment of Helicobacter pylori.
(FR) La présente invention concerne une composition pour prédire la sensibilité et la résistance à la clarithromycine d'Helicobacter pylori, comprenant une substance pour détecter le gène haploïde d'ARNr 23S dans lequel les bases dans les positions 2143 et 2182 du gène codant pour l'ARNr 23S bactérien sont respectivement A et T ou G et C; et un procédé de prédiction de la réactivité à la clarithromycine utilisant la composition. La composition et le procédé selon la présente invention peuvent prédire la réactivité à la clarithromycine d' Helicobacter pylori avec une grande précision et peuvent ainsi améliorer le taux de réussite d'un traitement d'éradication de première ligne d'Helicobacter pylori.
(KO) 본원은 박테리아 23S rRNA를 코딩하는 유전자의 2143번째 및 2182번째 염기가 각각 A 및 T; 또는 G 및 C인 23S rRNA 유전자 일배체 검출용 물질을 포함하는 헬리코박터 파이로리(Helicobacter pylori)의 클라리스로마이신 감수성 및 내성 예측용 조성물 및 상기 조성물을 이용한 클라리스로마이신 반응성 예측 방법을 개시한다. 본원에 따른 조성물 및 방법은 높은 정확도로 헬리코박터 파이로리의 클라리스로마이신 반응성 여부를 예측할 수 있어, 헬리코박터 파이로리 1차 제균 치료의 성공률을 높일 수 있다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)